Opioid Agonist class drugs

9 results

  • Dsuvia

    (Sufentanil)
    AcelRx Pharmaceuticals, Inc.
    Usage: DSUVIA is indicated for adults in certified healthcare settings for managing acute pain severe enough to require opioid analgesics when alternative treatments are inadequate. It is not for home use, children, or longer than 72 hours and must be administered by a healthcare provider.

  • Hysingla er

    (hydrocodone bitartrate)
    Purdue Pharma LP
    Usage: HYSINGLA ER is indicated for managing severe, persistent pain that necessitates long-term opioid treatment when alternative therapies are inadequate. It should be reserved for patients unable to tolerate non-opioid analgesics or immediate-release opioids due to concerns about addiction, abuse, and misuse. It is not for as-needed use.

  • Mitigo

    (Morphine Sulfate)
    Piramal Critical Care, Inc.
    Usage: MITIGO® is indicated for intrathecal or epidural infusion to manage intractable chronic pain requiring opioid analgesics when less invasive treatments are insufficient. It is not approved for single-dose administration or extended use unless pain severity justifies continued opioid therapy.

  • Nucynta

    (tapentadol hydrochloride)
    Collegium Pharmaceutical, Inc.
    Usage: NUCYNTA ER (tapentadol) is indicated for managing severe, persistent pain in adults requiring long-term opioid treatment when other options are inadequate, and for severe neuropathic pain related to diabetic peripheral neuropathy. It is not intended for as-needed use and carries risks of addiction and overdose.

  • Nucynta

    (tapentadol hydrochloride)
    Collegium Pharmaceutical, Inc.
    Usage: NUCYNTA (tapentadol) is indicated for the management of acute pain in adults and pediatric patients (ages 6 and older, weighing at least 40kg) when alternative treatments are inadequate. Due to addiction risks, it should only be used when necessary and not for extended periods.

  • Oxycontin

    (oxycodone hydrochloride)
    Purdue Pharma LP
    Usage: OXYCONTIN is indicated for the management of severe, persistent pain in adults and opioid-tolerant pediatric patients aged 11 and older requiring long-term opioid analgesia when alternative treatments are inadequate. It is not intended for as-needed use due to risks of addiction and overdose.

  • Qdolo

    (tramadol hydrochloride)
    Athena Bioscience, LLC
    Usage: QDOLO is indicated for the management of severe pain in adults when alternative treatments are inadequate. It should be used cautiously due to risks of addiction and abuse, and only when other analgesics are not tolerated or effective. Long-term use requires ongoing justification of severe pain.

  • Seglentis

    (celecoxib and tramadol hydrochloride)
    Kowa Pharmaceuticals America, Inc.
    Usage: SEGLENTIS is indicated for the management of acute severe pain in adults requiring opioid analgesics when alternative treatments are ineffective or intolerable. Due to addiction and misuse risks, it should only be used when other options fail to provide adequate relief.

  • Xtampza

    (OXYCODONE)
    Collegium Pharmaceutical, Inc.
    Usage: XTAMPZA ER is indicated for the management of severe, persistent pain requiring long-term opioid treatment when alternative options are inadequate. It is not recommended for as-needed use and should be reserved for patients at risk of addiction or misuse when other treatments fail.